Clinical trials NCT03132922 and NCT04044768 are evaluating T-cell therapies targeting MAGE-A4 in solid tumors, including SS, and have provided evidence of anti-tumor activity in patients with high antigen expression. This evidence concerns the gene MAGEA4 and synovial sarcoma.